Retatrutide (LY3437943) is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) studied for obesity and metabolic outcomes
"The influence of BPC 157 on nitric oxide synthesis in various models of inflammation and organ injury." Life Sci
My only hesitation in accepting the hypothesis that obesity is a downstream effect of hypothalamic inflammation lies in the fact that, in metabolically healthy individuals, a normally functioning digestive system, a non-steatotic liver, nutrient-sensitive pancreas and intestine, insulin-sensitive adipose tissue, should mitigate, at least to some extent (though not completely), the negative effects of an unhealthy diet, until their compensatory capacity fails
The limited human evidence includes: A randomised double-blind placebo-controlled Phase 2 enema trial in ulcerative colitis with 53 participants, published only as a meeting abstract
Results vary based on your starting levels and lifestyle